Clinical Trial Detail

NCT ID NCT01933932
Title Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors AstraZeneca

lung non-small cell carcinoma


Docetaxel + Selumetinib

Age Groups: adult

Additional content available in CKB BOOST